Catheter Precision Inc. (NYSE American: VTAK) is currently drawing attention. spotlight by “Cardiac Rhythm News” a trusted, independent news source worldwide located in London, United Kingdom, on Tuesday underscored the significance of Catheter Precision’s innovative strides in the cardiac treatment sector. Interest in companies advancing cardiac treatment is consistently high, especially when its VIVO™ 3D Mapping System secured reimbursement approval from England’s Specialized Services Devices Program (SSDP) at the National Health Service (NHS) in the United Kingdom.
VIVO™ 3D Mapping System’s revolutionary potential, is its non-invasive alternative to traditional methods that are often invasive, time-consuming, and not consistently successful. VIVO™ is employed before procedures commence, displaying a reduction in mapping time of up to 30% in clinical studies. This efficiency not only shortens procedure duration but also streamlines workflows.
It’s crucial to highlight that the SSDP was previously known as the HCTED (High-Cost Tariff Excluded Devices), and the inclusion paves the way for comprehensive reimbursement for the utilization of the VIVO™ 3D Mapping System. This inclusion is expected to enhance the accessibility of the product worldwide. Investors should note that this device represents a significant advancement in cardiovascular treatments, particularly in the early detection of cardiac arrhythmias before medical procedures.
Investors may find it opportune to monitor updates on “Cardiac Rhythm News” for further developments related to the VIVO™ 3D Mapping System. Notably, VTAK stock demonstrated a 9% gain in Tuesday’s trading session, accompanied by higher-than-average trading volume. This positive market response underscores the growing interest and confidence in Catheter Precision Inc.’s advancements in the cardiac treatment space. See complete news article: https://cardiacrhythmnews.com/catheter-precisions-vivo-3d-mapping-system-secures-reimbursement-in-nhs-englands-ssdp/